Aug 18, 2025 • Benzinga
SOMEWHAT-BULLISH
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Krystal Biotech ( NASDAQ:KRYS )
Krystal Biotech KRYS has outperformed the market over the past 5 years by 12.38% on an annualized basis producing an average annual return of 26.0%. Currently, Krystal Biotech has a market capitalization of $4.32 billion.
Aug 08, 2025 • Motley Fool
SOMEWHAT-BULLISH
Quoin ( QNRX ) Q2 Loss Beats Estimates
Quoin Pharmaceuticals ( NASDAQ:QNRX ) , a clinical-stage biotech focused on rare dermatological diseases, announced its second quarter 2025 results on August 7, 2025. The highlight was a net loss per American Depositary Share ( ADS ) of $ ( 6.28 ) ( GAAP ) , which beat the consensus GAAP estimate ...
Aug 05, 2025 • Zacks Commentary
NEUTRAL
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
Aug 04, 2025 • Benzinga
NEUTRAL
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - CommScope Holding Co ( NASDAQ:COMM ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.27% to 44,141.11 while the NASDAQ climbed 1.82% to 21,026.44. The S&P 500 also rose, gaining, 1.37% to 6,323.33. Communication services shares jumped by 2.3% on Monday.
Aug 04, 2025 • Motley Fool
SOMEWHAT-BULLISH
Krystal ( KRYS ) Q2 Profit Jumps 143%
Krystal Biotech ( NASDAQ:KRYS ) , a gene therapy company specialized in rare skin and genetic diseases, reported its latest quarterly results on August 4, 2025, for the second quarter of fiscal 2025. The company posted better-than-expected financials, reporting GAAP earnings per share of $1.29 ...
Aug 04, 2025 • Zacks Commentary
NEUTRAL
Krystal Biotech, Inc. ( KRYS ) Tops Q2 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?